Facebook Google Plus Instagram LinkedIn Twitter

Read the latest M. bovis facts & figures / Weekly Update - 15 October 2021

COVID-19 information

Terms of Reference – key elements

The key elements of the terms of reference are:

Purpose of the review

The 2019 National Plan for Mycoplasma bovis sets out three clear goals: to eradicate M. bovis from New Zealand; to reduce the impact of the disease and the eradication programme for everyone affected; and to leave New Zealand’s biosecurity system stronger.

The review team will conduct a forward looking review which will inform our biosecurity readiness and response to future animal disease incursions. The review will determine the partners ability to learn the lessons from a disease that effects animal health and productivity and translate those lessons into the necessary steps to reduce more serious risks to production, trade, food and economic security from livestock diseases.

What’s in Scope

  • New Zealand’s collective capacity and capability to deal with M. bovis and the parallels relating to our ability to mount a future FMD response,
  • The sector’s ability to learn the lessons from M. bovis (a disease that effects animal health and productivity) but then translate the lesson into the necessary steps to reduce more serious risks to production, trade, food and economic security.
  • What significant step changes were made over the life of the programme that made the response run better.
  • What were the limiting factors that contributed to system drag within disease control.
  • The capabilities that have been developed over the life of the Programme and how they could be managed in the future.
  • The implementation of the Operational Agreement for M. bovis between the partners
  • Relationship components
  • Communications
  • The management and governance frameworks in the context of a biosecurity response to ensure that it is fit for purpose for the next phase of the programme – and services the GIA Partnership.
  • Decisions made by governance and programme leadership level (excluding individual cases)
  • Programme/ system capabilities such as:
    • Epidemiology
    • Tracing
    • Response

What’s out of Scope

The review won’t:

  1. Examine the source of the disease
  2. Consider the biological and technical feasibility of eradication
  3. Examine the merits of the decision to eradicate
  4. Review the GIA framework
  5. Appraise the OA set up – i.e. changes to the current programmes, funding profile or operational agreement settings
  6. Consider the level of compensation

Accountability

The review team will report progress to the independent subcommittee of the Governance Group who, in turn, will report to the whole Governance Group.

Responsibilities

The responsibilities of the review team are:

  1. To contemplate New Zealand’s collective capacity and capability to deal with bovis and the parallels relating to our ability to mount a future FMD response and strengthen the biosecurity system.

  2. Provide insights and recommendations based on the following strategic themes:
  • Governance, decision making and cost sharing under a partnership model
  • Relationships and engagement (including communications and stakeholder engagement)
  • Capability (including at least - veterinary services, epidemiology, laboratory, tracing, response, compensation, human welfare, recovery, compensation)
  • Operational and logistics functions, including the application of regulatory powers
  • Information systems for tracking and tracing, incl. functionality, data integrity, accuracy and completeness, and interoperability with dependant systems,
  • Human welfare and social impacts at key points in the response timeline (e.g. incursion start, decision to respond, etc)
  • Recovery
  • Relationship management
  • Finance and procurement processes including use of contractors
  • Health, safety and wellbeing
  • OA implementation
  • Mechanisms to facilitate enduring change
  1. Maintain direct communication with the independent Chair of the Governance Group or Executive Director.

  2. Ensure there are no surprises by elevating for discussion with the oversight committee any matter that the review team considers worthy of consideration by the Governance Group, or by bringing to the attention of the oversight committee, any matter that the review team considers necessary.

Oversight 

The Governance Group has appointed a subcommittee of the Governance Group to oversee the conduct of the review.  It will be made up of the Independent Chair (Kelvan Smith) and independent members versed in review governance. 

Review and Reports

The key deliverable will be a report, together with an agreed set of recommendations for the M. bovis Governance group on how a partnership model readiness and response could be strengthened.

The final report will be supported by reports at formal review points, a draft report, verbal updates and advice as and when necessary to ensure that there are no surprises.

Reasonable notice of meetings and consultation forums shall be given to all invited participants.

Minutes of all meetings and the objectives, agendas and outputs will be kept.

Assumptions & Dependencies 

The following has been assumed:

  • The review be conducted from February 2021 until to a date to be reported by the oversight committee. 
  • The completion of the review will, if timing permits, consider the findings of other reviews currently in flight such as, but not limited to, the GIA deed review, Biosecurity Act Review and if relevant, and other GIA operational reviews (eg. Fruitfly).
  • The cost will be borne by the M. Bovis programme.

 

Constraints
Nil.